Filing Flows › Ovid Therapeutics (OVID) › Q1 2025
Ovid Therapeutics (OVID) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Ovid Therapeutics (OVID) reported revenue of $130K for the first quarter 2025 (Q1 2025), -12% from a year earlier and +71% from the quarter before.
Ovid Therapeutics, Q1 2025: revenue $130K (-12% year over year), net loss $10.2M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $130K | +71% | -12% |
| Operating profit | −$12.6M | — | — |
| Net earnings | −$10.2M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $130K in Q1 2025, down 12% year over year and up 71% from the previous quarter.
Operating costs exceeded revenue by $12.6M, an operating margin of -9653.8%. Total costs fell 28% while revenue fell 12%. The quarter ended with a net loss of $10.2M, wider than the previous quarter's $9.3M loss. Non-operating items added $2.3M, -23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.3M. Non-cash charges added back $141K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $1.5M.
Questions
What was Ovid Therapeutics' revenue in the first quarter 2025?
Ovid Therapeutics (OVID) reported revenue of $130K for the first quarter 2025 (Q1 2025), -12% from a year earlier and +71% from the quarter before.
Source: Ovid Therapeutics 10-Q on SEC EDGAR.